Skip to main content
. 2019 Dec 5;13(12):e0007856. doi: 10.1371/journal.pntd.0007856

Fig 3. Cost-effectiveness acceptability curve.

Fig 3

MA: meglumine antimoniate; IL-MA: meglumine antimoniate intralesional infiltration.